PSP Research LLC Invests $569,000 in Pharvaris N.V. $PHVS

PSP Research LLC acquired a new position in Pharvaris N.V. (NASDAQ:PHVS) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 20,511 shares of the company’s stock, valued at approximately $569,000. Pharvaris comprises about 0.5% of PSP Research LLC’s investment portfolio, making the stock its 5th biggest holding.

Several other large investors have also recently made changes to their positions in PHVS. Geode Capital Management LLC lifted its holdings in shares of Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock worth $952,000 after acquiring an additional 15,769 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the last quarter. Legal & General Group Plc lifted its holdings in shares of Pharvaris by 17.2% in the 2nd quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the last quarter. Amundi lifted its holdings in shares of Pharvaris by 2,741,600.0% in the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after acquiring an additional 27,416 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Pharvaris by 19.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock worth $860,000 after acquiring an additional 7,879 shares during the last quarter.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: HC Wainwright raised its earnings estimates for Pharvaris across multiple quarters and fiscal years, including higher forecasts for FY2026 through FY2030, and maintained a Buy rating with a $60 price target.
• Neutral Sentiment: Pharvaris recently reported a smaller-than-expected quarterly loss, with EPS of ($0.70) versus the consensus estimate of ($0.82), which may support sentiment but does not change the company’s near-term loss profile.
• Negative Sentiment: Insider selling by Director Robert Glassman and insider Wim Souverijns, both of whom sold 10,000 shares, may temper enthusiasm slightly because it can be viewed as reduced insider confidence. SEC filing for Robert Glassman sale SEC filing for Wim Souverijns sale

Insiders Place Their Bets

In other news, Director Johannes Gerardus Chri Schikan sold 29,070 shares of the company’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.32, for a total value of $881,402.40. Following the completion of the transaction, the director owned 355,167 shares in the company, valued at approximately $10,768,663.44. This represents a 7.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Anne Lesage sold 21,700 shares of the company’s stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $30.26, for a total transaction of $656,642.00. Following the completion of the transaction, the insider owned 56,450 shares of the company’s stock, valued at approximately $1,708,177. The trade was a 27.77% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 170,659 shares of company stock worth $5,086,987.

Pharvaris Trading Up 0.5%

Shares of NASDAQ:PHVS opened at $28.95 on Wednesday. Pharvaris N.V. has a 52 week low of $15.46 and a 52 week high of $33.33. The company’s 50 day moving average is $28.26 and its two-hundred day moving average is $26.68. The company has a market cap of $1.89 billion, a PE ratio of -9.10 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.12. As a group, equities research analysts expect that Pharvaris N.V. will post -3.25 EPS for the current year.

Wall Street Analysts Forecast Growth

PHVS has been the topic of several recent analyst reports. Royal Bank Of Canada decreased their price objective on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a report on Monday, April 6th. Wedbush upped their price objective on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. Citizens Jmp cut their target price on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating on the stock in a research note on Wednesday, May 13th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Pharvaris in a research note on Tuesday, March 3rd. Finally, Wall Street Zen raised shares of Pharvaris from a “strong sell” rating to a “sell” rating in a research note on Saturday. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.